Sun Pharmaceutical Industries agreed to buy U.S.-listed Organon & Co in an all‑cash deal valued at about $11.75 billion.
Organon shareholders will receive $14 per share, sending Organon stock up roughly 15% in early pre‑market trading.
Combined pro‑forma revenue projected at $12.4 billion, positioning the merged firm among top‑25 global pharma and a top‑3 women’s health player.
Deal financed via cash and committed bank funding, expected to close early 2027 pending regulatory and shareholder approvals.